vs
EXELIXIS, INC.（EXEL）与RBC Bearings INC（RBC）财务数据对比。点击上方公司名可切换其他公司
EXELIXIS, INC.的季度营收约是RBC Bearings INC的1.3倍（$598.7M vs $461.6M），EXELIXIS, INC.净利率更高（40.8% vs 14.6%，领先26.2%），RBC Bearings INC同比增速更快（17.0% vs 5.6%），EXELIXIS, INC.自由现金流更多（$332.4M vs $99.1M），过去两年EXELIXIS, INC.的营收复合增速更高（18.7% vs 5.6%）
Exelixis是一家总部位于美国加利福尼亚州阿拉米达的基因组学药物研发企业，专注于创新抗肿瘤药物开发，旗下产品Cometriq已获美国FDA批准用于治疗甲状腺髓样癌，在其余多种转移性癌症治疗领域也已展现出良好临床活性。
该文本实际介绍的并非RBC Bearings，而是美国多佛公司。多佛是一家工业产品综合制造商，1955年成立，总部位于伊利诺伊州当纳斯格罗夫。2021年其业务分为五大板块：工程产品、清洁能源与加注、成像与识别、泵与工艺解决方案、气候与可持续技术，是标普500成分股，在纽约证券交易所上市。
EXEL vs RBC — 直观对比
营收规模更大
EXEL
是对方的1.3倍
$461.6M
营收增速更快
RBC
高出11.4%
5.6%
净利率更高
EXEL
高出26.2%
14.6%
自由现金流更多
EXEL
多$233.3M
$99.1M
两年增速更快
EXEL
近两年复合增速
5.6%
损益表 — Q4 FY2025 vs Q3 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $598.7M | $461.6M |
| 净利润 | $244.5M | $67.4M |
| 毛利率 | 95.6% | 44.3% |
| 营业利润率 | 39.3% | 22.3% |
| 净利率 | 40.8% | 14.6% |
| 营收同比 | 5.6% | 17.0% |
| 净利润同比 | 74.8% | 16.4% |
| 每股收益（稀释后） | $0.89 | $2.13 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收EXELRBC
| Q1 26 | $598.7M | — | ||
| Q4 25 | $597.8M | $461.6M | ||
| Q3 25 | $568.3M | $455.3M | ||
| Q2 25 | $555.4M | $436.0M | ||
| Q1 25 | $566.8M | $437.7M | ||
| Q4 24 | — | $394.4M | ||
| Q3 24 | $539.5M | $397.9M | ||
| Q2 24 | $637.2M | $406.3M |
净利润EXELRBC
| Q1 26 | $244.5M | — | ||
| Q4 25 | $193.6M | $67.4M | ||
| Q3 25 | $184.8M | $60.0M | ||
| Q2 25 | $159.6M | $68.5M | ||
| Q1 25 | $139.9M | $72.7M | ||
| Q4 24 | — | $57.9M | ||
| Q3 24 | $118.0M | $54.2M | ||
| Q2 24 | $226.1M | $61.4M |
毛利率EXELRBC
| Q1 26 | 95.6% | — | ||
| Q4 25 | 96.9% | 44.3% | ||
| Q3 25 | 96.6% | 44.1% | ||
| Q2 25 | 96.5% | 44.8% | ||
| Q1 25 | 96.5% | 44.2% | ||
| Q4 24 | — | 44.3% | ||
| Q3 24 | 96.8% | 43.7% | ||
| Q2 24 | 97.2% | 45.3% |
营业利润率EXELRBC
| Q1 26 | 39.3% | — | ||
| Q4 25 | 39.6% | 22.3% | ||
| Q3 25 | 37.6% | 21.5% | ||
| Q2 25 | 33.6% | 23.2% | ||
| Q1 25 | 28.8% | 23.0% | ||
| Q4 24 | — | 21.7% | ||
| Q3 24 | 25.2% | 21.6% | ||
| Q2 24 | 43.3% | 24.0% |
净利率EXELRBC
| Q1 26 | 40.8% | — | ||
| Q4 25 | 32.4% | 14.6% | ||
| Q3 25 | 32.5% | 13.2% | ||
| Q2 25 | 28.7% | 15.7% | ||
| Q1 25 | 24.7% | 16.6% | ||
| Q4 24 | — | 14.7% | ||
| Q3 24 | 21.9% | 13.6% | ||
| Q2 24 | 35.5% | 15.1% |
每股收益（稀释后）EXELRBC
| Q1 26 | $0.89 | — | ||
| Q4 25 | $0.69 | $2.13 | ||
| Q3 25 | $0.65 | $1.90 | ||
| Q2 25 | $0.55 | $2.17 | ||
| Q1 25 | $0.47 | $2.33 | ||
| Q4 24 | — | $1.82 | ||
| Q3 24 | $0.40 | $1.65 | ||
| Q2 24 | $0.77 | $1.90 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $1.1B | $107.6M |
| 总债务越低越好 | — | $990.2M |
| 股东权益账面价值 | $2.2B | $3.3B |
| 总资产 | $2.8B | $5.1B |
| 负债/权益比越低杠杆越低 | — | 0.30× |
8季度趋势，按日历期对齐
现金及短期投资EXELRBC
| Q1 26 | $1.1B | — | ||
| Q4 25 | $988.5M | $107.6M | ||
| Q3 25 | $791.1M | $91.2M | ||
| Q2 25 | $1.0B | $132.9M | ||
| Q1 25 | $1.1B | $36.8M | ||
| Q4 24 | — | — | ||
| Q3 24 | $1.2B | — | ||
| Q2 24 | $1.0B | $76.8M |
总债务EXELRBC
| Q1 26 | — | — | ||
| Q4 25 | — | $990.2M | ||
| Q3 25 | — | $1.1B | ||
| Q2 25 | — | $915.6M | ||
| Q1 25 | — | $920.1M | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
股东权益EXELRBC
| Q1 26 | $2.2B | — | ||
| Q4 25 | $2.2B | $3.3B | ||
| Q3 25 | $2.0B | $3.2B | ||
| Q2 25 | $2.1B | $3.1B | ||
| Q1 25 | $2.2B | $3.0B | ||
| Q4 24 | — | $2.9B | ||
| Q3 24 | $2.3B | $2.9B | ||
| Q2 24 | $2.1B | $2.8B |
总资产EXELRBC
| Q1 26 | $2.8B | — | ||
| Q4 25 | $2.8B | $5.1B | ||
| Q3 25 | $2.7B | $5.1B | ||
| Q2 25 | $2.8B | $4.8B | ||
| Q1 25 | $2.9B | $4.7B | ||
| Q4 24 | — | $4.7B | ||
| Q3 24 | $3.0B | $4.7B | ||
| Q2 24 | $2.8B | $4.7B |
负债/权益比EXELRBC
| Q1 26 | — | — | ||
| Q4 25 | — | 0.30× | ||
| Q3 25 | — | 0.34× | ||
| Q2 25 | — | 0.29× | ||
| Q1 25 | — | 0.30× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $333.5M | $122.1M |
| 自由现金流经营现金流 - 资本支出 | $332.4M | $99.1M |
| 自由现金流率自由现金流/营收 | 55.5% | 21.5% |
| 资本支出强度资本支出/营收 | 0.2% | 5.0% |
| 现金转化率经营现金流/净利润 | 1.36× | 1.81× |
| 过去12个月自由现金流最近4个季度 | $875.8M | — |
8季度趋势，按日历期对齐
经营现金流EXELRBC
| Q1 26 | $333.5M | — | ||
| Q4 25 | $290.3M | $122.1M | ||
| Q3 25 | $49.0M | $88.4M | ||
| Q2 25 | $211.4M | $120.0M | ||
| Q1 25 | $240.3M | — | ||
| Q4 24 | — | $84.0M | ||
| Q3 24 | $271.3M | — | ||
| Q2 24 | $119.5M | $97.4M |
自由现金流EXELRBC
| Q1 26 | $332.4M | — | ||
| Q4 25 | $288.8M | $99.1M | ||
| Q3 25 | $46.2M | $71.7M | ||
| Q2 25 | $208.5M | $104.3M | ||
| Q1 25 | $236.3M | — | ||
| Q4 24 | — | $73.6M | ||
| Q3 24 | $263.1M | — | ||
| Q2 24 | $113.0M | $88.4M |
自由现金流率EXELRBC
| Q1 26 | 55.5% | — | ||
| Q4 25 | 48.3% | 21.5% | ||
| Q3 25 | 8.1% | 15.7% | ||
| Q2 25 | 37.5% | 23.9% | ||
| Q1 25 | 41.7% | — | ||
| Q4 24 | — | 18.7% | ||
| Q3 24 | 48.8% | — | ||
| Q2 24 | 17.7% | 21.8% |
资本支出强度EXELRBC
| Q1 26 | 0.2% | — | ||
| Q4 25 | 0.2% | 5.0% | ||
| Q3 25 | 0.5% | 3.7% | ||
| Q2 25 | 0.5% | 3.6% | ||
| Q1 25 | 0.7% | 3.2% | ||
| Q4 24 | — | 2.6% | ||
| Q3 24 | 1.5% | 4.1% | ||
| Q2 24 | 1.0% | 2.2% |
现金转化率EXELRBC
| Q1 26 | 1.36× | — | ||
| Q4 25 | 1.50× | 1.81× | ||
| Q3 25 | 0.27× | 1.47× | ||
| Q2 25 | 1.32× | 1.75× | ||
| Q1 25 | 1.72× | — | ||
| Q4 24 | — | 1.45× | ||
| Q3 24 | 2.30× | — | ||
| Q2 24 | 0.53× | 1.59× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
EXEL
| Cabometyx | $544.7M | 91% |
| Collaboration | $52.1M | 9% |
| Collaborative Arrangementwith Takeda | $5.9M | 1% |
| Cometriq | $1.8M | 0% |
RBC
| Domestic | $413.3M | 90% |
| Foreign | $48.3M | 10% |
